Dydrogesterone and other progestins in benign breast disease: an overview

  title={Dydrogesterone and other progestins in benign breast disease: an overview},
  author={Adolf Eduard Schindler},
  journal={Archives of Gynecology and Obstetrics},
  • A. Schindler
  • Published 1 February 2011
  • Medicine
  • Archives of Gynecology and Obstetrics
Progestogens appear to have a dual effect on the cell cycle in breast cells and breast cancer cells. There is initially stimulation of mitotic activity. However, continuous application leads to cell apoptosis. This depends on type, dose and length of progestogen application in relation to estrogen action. In benign breast disease the use of progestogens results not only in reduction of mastodynia, but also a reduction in breast gland size and disappearance of nodularity proven by clinical… 

Successful use of dydrogesterone as maintenance therapy in recurrent endometrial stromal sarcoma: a case report.

Dydrogesterone at a daily dose of 10 mg may be effective in treating low-grade endometrial stromal sarcoma, which is alive with slight disease 9 years and 6 months after the initial failure.

Anti-hyperplasia Effects of Total Saponins From Phytolaccae Radix in Rats With Mammary Gland Hyperplasia via Inhibition of Proliferation and Induction of Apoptosis

Investigating the protective effects and underlying mechanism of total saponins of Phytolaccae (TSP) against MGH in vivo showed that treatment with TSP could significantly correct the disorder of serum sex hormones levels in rats with MGH, and eliminate the formation of MGH.

Thiol - Dependent Sensitization of Mitochondria and Tumor Cells to Doxorubicin

By contrast to NEM, which irreversibly blocks thiol groups, buterol binds thiols non-covalently, which provides a new useful approach to the enhancement of the anticancer activity of cytostatics in tumor cells.

Effect of steroid hormones on production of reactive oxygen species in mitochondria

It was found that progesterone promoted formation of superoxide anion and hydrogen peroxide in mitochondria oxidizing the substrates of complex I of the respiratory chain but did not influence the production of ROS during oxidation of succinate, respiratory chain complex II substrate.



Dienogest and the breast

In a clinical pilot study, 21 women with endometriosis have been primarely treated with dienogest 2 × 10 mg daily p.o.s. for 24 weeks and the action of such high-dose progestogen treatment on the breast was evaluated by breast ultrasound prior to medication and at 24 weeks of medical treatment.

Progestogen Use and Risk of Breast Cancer

The results suggest that progestin use was not associated with increased breast cancer risk in this population of women with benign breast disease and suggest that some types of progestins might have a beneficial effect on the risk of breast cancer.

Progestins and breast cancer

  • J. Pasqualini
  • Biology
    The Journal of steroid biochemistry and molecular biology
  • 1998
In order to clarify and better understand the response of progestins in breast cancer (incidence, mortality), as well as in hormone replacement therapy or endocrine dysfunction, new clinical trials are needed studying other progestin compounds as a function of the dose and period of treatment.

The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells.

The in vitro results indicate that the influence on breast cancer risk using HRT in postmenopausal women might depend on the type of progestin used as well as on the regimen applied, and whether progesterone and various synthetic C19- and C21-progestins in general can reduce cancer risk in long-term treatment remains uncertain.

Cyclic progestin therapy for the management of mastopathy and mastodynia

Cyclic administration of the low-dose progestins medrogestone and dydrogesterone proved to be an effective and safe treatment of mastodynia and mastopathy and palpatory findings and sonographic imaging of breast nodules and cysts improved.

Estrogen plus Progestin and Risk of Benign Proliferative Breast Disease

The results of this study suggest that the use of estrogen plus progestin may increase the risk of benign proliferative breast disease.

Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease.

Treatment with 19-nortestosterone derivatives might have a beneficial effect on the risk of breast cancer in women with benign breast disease and support the hypothesis that progestogens might increase the breast cancer risk.

Progestins and Antiprogestins in Clinical Practice

Progestins in Hormonal Replacement Therapy and Cardiovascular Risk, Breast Diseases, andTherapeutic Use of Progestins: Practical Recommendations, metabolic effects of Progesterone, and clinical applications.

Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.

The proto-oncogenes c-fos and c-myc were rapidly but transiently induced by progestin treatment, paralleling the well-known response of these genes to mitogenic signals in other cell types.